Harvard Bioscience Earnings Call Signals Gradual Recovery

Harvard Bioscience ((HBIO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Harvard Bioscience’s latest earnings call struck a cautiously optimistic note as management balanced solid operational gains with lingering top-line pressure. Executives pointed to higher margins, stronger cash flow and a cleaner balance sheet as signs of progress, yet acknowledged that revenue remains below prior-year levels and that macro and funding headwinds are still in play.

Q4 Revenue Beats Midpoint but Still Trails Last Year

Harvard Bioscience reported fourth quarter revenue of $23.7 million, slightly above the midpoint of its $22.5–$24.5 million guidance and up 15% sequentially, signaling a rebound late in the year. However, sales were still below the $24.6 million posted in Q4 of the prior year, underscoring that the recovery remains incomplete.

Margin Expansion Delivers Best Levels in Nearly Two Years

Gross margin in the fourth quarter reached about 59.7%, essentially the high end of guidance and roughly 260 basis points above the 57.1% level a year earlier. Management highlighted that this was the strongest gross margin performance in the last seven quarters, reflecting mix improvements and operational efficiencies.

Adjusted EBITDA Strength Offsets GAAP Earnings Weakness

Adjusted EBITDA in Q4 came in at $3.8 million, a 27% year-over-year increase, while full-year adjusted EBITDA rose to $8.1 million from $7.2 million. These non-GAAP gains contrasted sharply with GAAP losses, reinforcing management’s message that underlying operations are improving despite headline earnings pressure.

Cash Flow Gains Support Deleveraging Effort

Cash flow from operations improved significantly to $6.7 million, up from $1.4 million at the end of the prior year, as working capital tightened and profitability improved. Net debt declined by $1.8 million to $31.4 million, signaling tangible progress in deleveraging and enhancing balance sheet resilience.

Refinancing Cuts Interest Costs and Extends Runway

The company completed a comprehensive refinancing that extended debt maturities and reduced annual debt service to about $5 million. Management expects roughly $3 million in annual cash savings in the near term from lower interest and principal payments, giving more flexibility to fund growth and restructuring initiatives.

Manufacturing Consolidation Targets Structural Cost Savings

Harvard Bioscience announced a phased closure of its Holliston site and consolidation into Minneapolis and European centers of excellence. The move is expected to generate about $3 million of savings in 2027 and approximately $4 million annually thereafter, positioning the cost base for higher future margins.

Governance and Control Upgrades Bolster Credibility

Management underscored a stronger governance framework, citing the addition of four new board members, the creation of a product and scientific advisory board, and the appointment of a permanent CFO. The company also reported remediation of material weaknesses and a significant control deficiency, aiming to reduce risk around reporting and execution.

Shift Toward Higher-Margin Platforms and Recurring Revenue

Strategically, the company is focusing on translational science and higher-margin platform products such as SoHo telemetry, BTX for bioproduction, Mesh MEA and Incub8. Management expects BTX and Mesh MEA to grow at double-digit rates in 2026 and continues to push recurring revenue, which already stands at roughly 55% of total sales.

Backlog and Asia Strength Offer Early Demand Signals

Harvard Bioscience ended the year with its highest backlog in more than two years, providing better visibility into near-term demand. China and Asia Pacific revenue grew about 10% year over year in Q4 on catch-up orders, and management expects a more normal cadence going forward, assuming no adverse tariff developments.

Full-Year Revenue Decline Highlights Demand Challenges

For 2025, full-year revenue fell to $86.6 million from $94.1 million, an 8% decline driven largely by tariffs and delayed U.S. funding that pushed out orders, especially in preclinical telemetry. The softness shows that while operations are tightening, end-market demand and funding timing remain critical variables.

Goodwill Impairment Drives Large GAAP Loss

Full-year GAAP operating income deteriorated to a loss of $48.6 million from a $6.2 million loss in the prior year, largely due to a sizeable earlier goodwill impairment. GAAP loss per share widened to $1.28 from $0.28, a swing that overshadowed the underlying operational improvement presented in adjusted metrics.

Adjusted EPS and Share Metrics Remain Under Pressure

On an adjusted basis, the company posted a full-year loss per share of $0.02 compared with adjusted earnings of $0.03 previously. In the fourth quarter, GAAP earnings per share were a loss of $0.06 versus roughly break-even last year, and adjusted Q4 EPS showed only limited progress, reflecting ongoing revenue pressure.

Regional Weakness in Europe and Americas Weighs on Growth

Regionally, Q4 revenue in Europe declined about 12% year over year and was down roughly 6% for the full year, hurt by softer academic and distribution sales. The Americas were also weak, with Q4 revenue down about 2% and full-year sales off roughly 7%, mainly due to lower academic and pharma preclinical demand.

Reliance on NIH Funding and Tariff Risk Adds Volatility

Management noted that delays in U.S. funding significantly disrupted order timing, with U.S. funding representing around 20% of domestic revenue and particularly impacting preclinical telemetry. Tariffs earlier in the year also weighed on China and Asia Pacific, and executives cautioned that changes in tariff policy could quickly reverse recent gains in the region.

Non-Cash Charges Distort Comparison Between GAAP and Non-GAAP

Executives argued that large non-operational items, including the goodwill impairment, stock-based compensation and amortization, heavily influenced GAAP results. These charges widened the gap between GAAP and non-GAAP performance and contributed to the sizable reported loss, even as cash generation and adjusted metrics improved.

Reinstated Compensation to Temper Near-Term EBITDA Growth

Looking ahead, management flagged that the reinstatement of bonuses and merit-based pay in 2026, which were suspended in 2025, will put pressure on year-over-year adjusted EBITDA comparisons. This headwind is already reflected in guidance, signaling that EBITDA growth will be modest despite underlying operational gains.

Forward Guidance Points to Gradual, NPI-Led Recovery

For 2026, Harvard Bioscience guided to first quarter revenue of $20–$22 million, adjusted gross margin of 57%–59% and adjusted EBITDA of $1–$2.2 million. Full-year guidance calls for 2%–4% revenue growth on 2025’s base, adjusted gross margin of 58%–60% and 6%–10% adjusted EBITDA growth, with a second-half ramp driven by stronger BTX and Mesh MEA demand.

Harvard Bioscience’s earnings call painted a picture of a company steadily shoring up its foundation while waiting for growth to catch up. Margin gains, better cash flow and lower debt are clear positives, but revenue softness, funding and tariff risks and modest guidance keep expectations grounded, leaving investors to watch whether new products can spark a more durable upturn.